Trial Profile
A Phase II Trial of STI-571/Imatinib (Gleevec (R)) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- 12 Jan 2012 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 12 Jan 2012 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.
- 12 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.